Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Esophageal Squamous Cell Carcinoma

OncoTree code ESCC · 2 articles

Clinical

For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis

Ju F, Ji Y

Drug design, development and therapy

A retrospective study evaluated the efficacy and safety of first-line camrelizumab combined with chemotherapy (nab-paclitaxel and cisplatin) for advanced oesophageal squamous cell carcinoma (OSCC), compared to PD-1 monotherapy or chemotherapy alone. The study, involving 253 patients, demonstrated that the combination significantly improved progression-free survival (PFS) compared to the other arms. Although objective response and disease control rates did not differ, median overall survival was longest in the combination group (12.0 months). Adverse events were manageable, with higher rates of anemia and neutropenia in the combination group. An elevated neutrophil-to-lymphocyte ratio (NLR) was identified as an independent prognostic biomarker.

Clinical · Molecular biology · Bioinfo & AI

[Dynamically monitoring circulating tumor DNA as a biomarker for immunotherapy in advanced esophageal squamous cell carcinoma]

Wang BY, Wang HK, Li J, et al.

Zhonghua zhong liu za zhi [Chinese journal of oncology]

This study investigated the clinical value of dynamic monitoring of circulating tumor DNA (ctDNA) in 94 patients with advanced esophageal squamous cell carcinoma (ESCC) receiving sintilimab. The findings indicate that the ctDNA-based molecular tumor burden index (mTBI) serves as a sensitive, real-time biomarker for evaluating immunotherapy efficacy. Patients achieving ctDNA clearance or having a low mTBI after two treatment cycles demonstrated significantly delayed tumor progression and improved overall survival. Dynamic mTBI monitoring showed high consistency with concurrent imaging assessments, suggesting its utility for personalized treatment management.